In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Roche presented early-stage data on its obesity injection and pill at EASD. Meanwhile, Oura enters into metabolic health ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription. And even when he got the drug, he waited a month before using it.

A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new trials ...

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

Deutsche Bank downgrades AstraZeneca (AZN) and Roche (RHHBY) after disappointing data for thier key pipeline assets. Read ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...